Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Clinical trial NCT02314247 · TERMINATED

Trial details

NCT number: NCT02314247
Sponsor: Karyopharm Therapeutics Inc
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)

Start date: 2015-02-01
Primary completion: 2016-01-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.